LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome

Adv Ther. 2008 Sep;25(9):894-913. doi: 10.1007/s12325-008-0093-z.


Introduction: This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen, Inc., La Jolla, CA, USA).

Methods: A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed.

Results: Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05), and increased energy (P<0.001). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-gamma2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment (r=0.42, P=0.045).

Conclusion: If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Obesity Agents / therapeutic use*
  • Appetite / drug effects
  • Cross-Sectional Studies
  • Dietary Supplements*
  • Feeding Behavior / drug effects
  • Genotype
  • Humans
  • Hyperphagia / drug therapy
  • Leptin / genetics
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • Obesity / genetics*
  • Obesity / therapy*
  • PPAR gamma / genetics
  • Polymorphism, Genetic*
  • Receptor, Serotonin, 5-HT2A / genetics
  • Receptors, Dopamine D2 / genetics
  • Retrospective Studies
  • Reward*
  • Syndrome
  • Weight Loss / drug effects


  • Anti-Obesity Agents
  • Leptin
  • PPAR gamma
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Dopamine D2
  • Methylenetetrahydrofolate Reductase (NADPH2)